Ventis Pharma introduces a groundbreaking solution designed for hospital boards seeking to improve postoperative care. Our revolutionary product, Enduracaine™, stands as a highly effective alternative to existing post-operative local anesthetics that have faced challenges in gaining widespread adoption. High toxicity, inefficacy, and exorbitant costs have hindered the success of current options.
Enduracaine™, Ventis Pharma’s new formulation, is currently undergoing US FDA IND tests and studies, paving the way for subsequent FDA clinical trials. This rigorous testing process is set to substantiate the product’s safety, efficiency, and effectiveness. Notably, Enduracaine™ combines existing, approved USP products, ensuring its use is safe and acceptable even prior to specific FDA approval through a New Drug Application.
Initial off-label trials, encompassing over 2500 patients, have yielded remarkable results. These trials have demonstrated substantial and enduring reductions in postoperative pain, coupled with a notable decrease in the necessity for additional medications, including opioids. The product has been met with remarkable acceptance by both patients and clinicians, with minimal adverse effects observed.
Enduracaine™ emerges as a groundbreaking pain relief solution suitable for a diverse array of surgical procedures. This innovation holds the promise of transforming postoperative care, aligning with hospital boards’ commitment to excellence and patient well-being.